Hypoglycaemia in Type 2 Diabetes – Clinical Consequences and Impact on Treatment by Barnett, Anthony H et al.
Hypoglycaemia is a common problem for many patients with diabetes
and the risks and consequences need to be considered when
prescribing therapy. Mild episodes can cause unpleasant symptoms
and disrupt daily activities, while severe hypoglycaemia can result in
disorientation and unusual behaviour, and may be life-threatening.
Frequent hypoglycaemia, as a complication of treatment, is
associated with increased morbidity and mortality, making it a limiting
factor in achieving adequate glycaemic control.1–6 In type 1 diabetes,
hypoglycaemia has been recognised as a major hurdle for optimal
glycaemic control for many years, with the Diabetes Control and
Complications Trial (DCCT) clearly indicating an inverse relationship
between lowering glycated haemoglobin (HbA1c) and the occurrence
of severe hypoglycaemia.7 Therefore, the most important beneficial
consequence of the introduction of insulin analogues in the treatment
of patients with type 1 diabetes is not a major improvement in HbA1c,
but rather a reduction in occurrence of hypoglycaemia.8
Although less frequent, many glucose-lowering therapies used in
patients with type 2 diabetes can also cause hypoglycaemia,
particularly sulphonylureas and insulin. Recent results from trials
including the Action to Control Cardiovascular Risk in Diabetes
(ACCORD) and the Veterans Affairs Diabetes Trial (VADT) have
stimulated discussion of the potential long-term cardiovascular (CV)
risk of hypoglycaemic events in patients with type 2 diabetes. The
importance of avoiding hypoglycaemia is becoming increasingly
considered in terms of diabetes care in both type 1 and 2 diabetes.
The true incidence of hypoglycaemia is unknown. Many episodes are
subclinical and go unnoticed by both the physician and the patient.
The frequency is likely to be significantly underestimated. The
objective of this article is to discuss the impact and clinical
implications of hypoglycaemia, with particular attention to people
with type 2 diabetes.
Definition of Hypoglycaemia
Hypoglycaemia has been defined as a plasma glucose level of
<70mg/dl (<3.9mmol/l), as once levels go below this threshold,
activation of the anti-insulin neuroendocrine counter-regulatory
response normally occurs.1,2 However, the definition of hypoglycaemia
used in clinical trials often varies between investigators and the
threshold may range from 55 to 70mg/dl (3 to 3.9mmol/l), leading to
different estimations of its incidence.9,10 By contrast, more descriptive
definitions have also been employed where the authors manually
review and classify subjects into ‘mild’ (not requiring third-party help)
or ‘severe’ (if the patient requires help).11 These different approaches to
defining hypoglycaemia make it difficult to pinpoint its exact incidence.
Frequency of Hypoglycaemia
Although the true frequency of hypoglycaemia is hard to determine, in
an analysis of 50,048 patients with type 2 diabetes, 4.1% suffered an
episode of hypoglycaemia while on treatment with oral antidiabetes
agents (OADs). In the same analysis, use of insulin was found to be a
significant risk factor for hypoglycaemia, as was sulphonylurea (SU)
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(adjusted odds ratio [OR] 3.73).11 By contrast, use of metformin was
associated with a comparatively low risk (OR 1.42) – i.e. hypoglycaemia
was nearly three times more common with SU than with metformin
treatment in the absence of insulin. The recorded frequencies of
hypoglycaemia in selected trials are listed in Table 1.
Causes of Hypoglycaemia
In patients with diabetes, causes of hypoglycaemia include missed or
delayed food intake, a meal or snack that is too small, vigorous
exercise without adequate carbohydrate compensation and alcohol
consumption.1 A major cause of hypoglycaemia in patients is the
medicine used to control glycaemia.12 Relative or absolute insulin
excess from therapy in combination with compromised physiological
defences against falling plasma glucose concentrations can lead to
hypoglycaemia.3,4 Insulin excess occurs because of an inadequate
action profile of the drug when placed in the context of factors such
as food intake, exercise, drug interactions and insulin clearance.1
Meanwhile, in type 1 and more advanced type 2 diabetes, there is
impairment of all three physiological defences that would normally
correct hypoglycaemia: there is no decrease in insulin levels, no
increase in glucagon levels and the increase in epinephrine
(adrenaline) levels may be attenuated, resulting in a higher
hypoglycaemia risk with insulin use.11,13,14
The potential of a specific OAD to cause hypoglycaemia is dependent on
its mechanism of action. For example, SUs are insulin secretagogues
and work by increasing insulin secretion regardless of blood glucose
levels, effectively uncoupling the glucose sensitivity of pancreatic 
islet beta-cells and insulin secretion, thus increasing the risk of
hypoglycaemia.15,16 By contrast, metformin does not directly stimulate
insulin secretion and therefore the risk of hypoglycaemia is low.11
Impaired Awareness of Hypoglycaemia
The initial symptoms of hypoglycaemia are largely triggered by
increased levels of epinephrine (adrenaline), one of the counter-
regulatory responses normally associated with low blood glucose.3,4
However, in many patients with type 1 and 2 diabetes of longer
duration, counter-regulatory responses are blunted – a
phenomenon known as hypoglycaemia-associated autonomic
failure (HAAF).4,17,18 This syndrome not only involves reduced
neuroendocrine counter-regulatory responses to lowered blood
glucose, but also lowered glycaemic thresholds for activation of
defences against hypoglycaemia. This latter can lead to
hypoglycaemia unawareness, which is the inability to perceive the
normal (early) warning symptoms of hypoglycaemia.
Studies suggest that even one prolonged, moderate episode of
hypoglycaemia may be sufficient to significantly reduce counter-
regulatory responses.19,20 Without the warning signs, episodes
become difficult to detect. Accordingly, the incidence of subclinical
hypoglycaemia cannot be determined accurately, although episodes
are common in insulin-treated patients.1 Indeed, the prevalence has
been estimated as high as 19.5% in patients with type 1 diabetes.21
The major risk associated with episodes of subclinical hypoglycaemia
is the potential for reduced awareness of the onset of a severe
episode because the glycaemic threshold has been substantially
lowered. In turn, a bout of recurrent episodes can lead to a vicious
cycle of hypoglycaemia, inducing further hypoglycaemia.17,18,22 Indeed,
subclinical hypoglycaemia (not surprisingly) is associated with a six-
fold increased risk of severe hypoglycaemia.21,23 In insulin-treated
patients with type 2 diabetes, the prevalence of impaired awareness
of hypoglycaemia has been estimated to be around 10%. Impaired
awareness of hypoglycaemia in this cohort was associated with a
five-fold higher incidence of hypoglycaemia and a 17-fold higher
incidence of severe episodes.10 On the other hand, studies suggest
that several weeks of stringent avoidance of hypoglycaemia can
reverse hypoglycaemia unawareness in the majority of patients.1,24–26
Hypoglycaemia and Long-term
Cardiovascular Morbidity and Mortality
In addition to the immediate consequences of hypoglycaemia,
episodes may also lead to other longer-term health consequences.
Three recently published studies have examined the effects of
intensive versus standard glycaemia treatment on CV risk in
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Table 1: Frequency of Hypoglycaemia from
Observational Studies in Outpatient Settings
Study Number Frequency of Hypoglycaemia 
Type 1 Type 2
Jennings et al., 1989a 219 20% of those
taking SU
Miller et al., 2000b 1,055 16% with OADs
30% with insulin
Shorr et al., 1997c 19,932 1.23 severe
episodes/100
person-years 
with SUs
2.76 severe
episodes/100
person-years 
with insulin
Gurlek et al., 1999d 165 0.15 severe 0.15 severe
episodes/patient/ episodes/patient/
year with insulin year with insulin
Leese et al., 2003e 160 7.1% requiring 7.3% requiring
emergency emergency
treatment treatment
Donnelly et al., 2005f 267 42.9 per 16.4 per 
patient/year patient/year
Henderson et al., 2003g 215 0.28 severe
episodes/patient/
year
MacLeod et al., 1993h 600 1.7 episodes/ 0.73 episodes/
patient/year patient/year
Hepburn et al., 1993i 172 82.7% with insulin
OADs = oral antidiabetes agents; SU = sulphonylurea.
a.  Jennings AM, Wilson RM, Ward JD, Symptomatic hypoglycaemia in NIDDM patients
treated with oral hypoglycaemic agents, Diabetes Care, 1989;12:203–8.
b.  Miller CD, Phillips LS, Ziemer DC, et al., Hypoglycaemia in patients with type 2 diabetes
mellitus, Arch Intern Med, 2001;161:1653–9.
c.  Shorr RI, Ray WA, Daugherty JR, et al., Incidence and risk factors for serious
hypoglycaemia in older persons using insulin or sulfonylureas, Arch Intern Med,
1997;157:1681–6.
d.  Gurlek A, Erbas T, Gedik O, Frequency of severe hypoglycaemia in type 1 and type 2
diabetes during conventional insulin therapy, Exp Clin Endocrinol Diabetes,
1999;107:220–24.
e.  Leese GP, Wang J, Broomhall J, et al., Frequency of severe hypoglycaemia requiring
emergency treatment in type 1 and type 2 diabetes: a population-based study of health
service resource use, Diabetes Care, 2003;26:1176–80.
f.  Donnelly LA, Morris AD, Frier BM, et al., Frequency and predictors of hypoglycaemia in
Type 1 and insulin-treated Type 2 diabetes: a population-based study, Diabet Med,
2005;22:749–55.
g.  Henderson JN, Allen KV, Deary IJ, et al., Hypoglycaemia in insulin-treated Type 2 diabetes:
frequency, symptoms and impaired awareness, Diabet Med, 2003;20:1016–21.
h.  MacLeod KM, Hepburn DA, Frier BM, Frequency and morbidity of severe hypoglycaemia
in insulin-treated diabetic patients, Diabet Med, 1993;10:238–45.
i.  Hepburn DA, MacLeod KM, Pell AC, et al., Frequency and symptoms of hypoglycaemia
experienced by patients with type 2 diabetes treated with insulin, Diabet Med,
1993;10:231–7.
patients with type 2 diabetes (see Table 2).27–29 In the three studies,
the incidence of hypoglycaemia was significantly higher in the
intensive therapy group. None found that near-normal glycaemic
control (median HbA1c of 6.4% at study end in the intensive group)
significantly reduced the incidence of CV events within a 3.5–5-year
time-frame.27–29
By contrast, the ACCORD trial found that overall mortality was greater
in the intensive therapy group.27–29 In 19 of the 41 unexpected excess
deaths from CV causes in the ACCORD study, ‘unexpected or
presumed CV disease’ was possibly related to, or precipitated 
by, severe hypoglycaemia.27–29 Interestingly, in the ACCORD 
study, previous occurrence of severe hypoglycaemia was one of 
the strongest predictors of a primary CV event regardless of the
treatment arm. In addition, while hypoglycaemic events were more
frequent in the intensive therapy group, this arm also saw a greater
increase in weight gain of more than 10kg. These factors, as well as
the differences in number of drugs and regimens, could have
contributed to the final mortality rates.
In VADT, hypoglycaemia was one of the strongest predictors 
of CV death (hazard ratio [HR] 4.042, 95% confidence interval [CI]
1.449–11.276; p=0.01); other predictors were prior event and age.30
CV risk may also be increased by recurrent subclinical hypoglycaemic
episodes as a low blood glucose level stimulates sympathetic neural
activation and catecholamine secretion, which can lead to arrhythmia
and increased heart rate, blood pressure and overall workload of the
heart.31 These haemodynamic changes can result in stress in the arterial
wall and may contribute to destabilisation of atherosclerotic plaques,
potentially precipitating an atherothrombotic event. Furthermore, acute
hypoglycaemia causes physiological changes that affect the CV system
and several haematological parameters, largely as a result of sympatho-
adrenal activation and counter-regulatory hormonal secretion.32
A study using healthy subjects found that antecedent hypoglycaemia
led to impaired autonomic function, which could potentially contribute
directly to mortality in diabetes and CV disease.33 By contrast, a study
focusing on patients hospitalised with acute myocardial infarction
(AMI) reported that hypoglycaemia only increased mortality when
episodes occurred spontaneously without insulin treatment (18.4%
mortality rate in patients with hypoglycaemia versus 9.2% in those
without).34 When hypoglycaemia was induced by insulin therapy, there
was no significant difference in mortality between patients who
suffered hypoglycaemia and those who did not (10.4 versus 10.2%).
Regardless of insulin treatment, the patients with hypoglycaemia were
older and had more co-morbidities.34 Finally, the data also suggest that
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Table 2: Comparison of the Three Trials of Intensive Glycaemic Control and Cardiovascular Disease Outcomes
ACCORD ADVANCE VADT
Participant Characteristics
Number 10,251 11,140 1,791
Mean age (years) 62 66 60
Duration of diabetes (years) 10 8 11.5
Sex (% male/female) 39/61 42/58 97/3
History of CVD (%) 35 32 40
BMI (kg/m2) 32 28 31
Median baseline HbA1c (%) 8.1 7.2 9.4
On insulin at baseline (%) 35 1.5 52
Protocol Characteristics
HbA1c goals (%) <6.0 versus 7.0–7.9 ≤6.5 versus ‘based on local guidelines’ <6.0 (action if >6.5) versus planned 
(I versus S)* separation of 1.5
Protocol for glycemic control Multiple drugs in both arms Multiple drugs added to gliclizide versus Multiple drugs in both arms
(I versus S)* multiple drugs with no gliclizide
Management of other risk factors Embedded blood pressure and Embedded blood pressure trial Protocol for intensive treatment in
lipid trials both arms
On-study Characteristics
Weight changes (kg):
Intensive glycaemic control arm +3.5 -0.1 +7.8
Standard glycaemic control arm +0.4 -1.0 +3.4
Severe hypoglycaemia (participants 
with one or more episodes during 
study) (%):
Intensive glycaemic control arm 16.2 2.7 21.2
Standard glycaemic control arm 5.1 1.5 9.9
Outcomes
Definition of primary outcome Non-fatal MI, non-fatal stroke, Microvascular plus macrovascular Non-fatal MI, non-fatal stroke, CVD
CVD death (non-fatal MI, non-fatal stroke, CVD death, hospitalisation for heart failure,
death) outcomes revascularisation
HR for primary outcome (95% CI) 0.90 (0.78–1.04) 0.9 (0.82–0.98); macrovascular 0.94 0.88 (0.74–1.05)
(0.84–1.06)
HR for mortality findings (95% CI) 1.22 (1.01–1.46) 0.93 (0.83–1.06) 1.07 (0.81–1.42)
ACCORD = Action to Control Cardiovascular Risk in Diabetes; ADVANCE = Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation; 
VADT = Veterans Affairs Diabetes Trial; CVD = cardiovascular disease; I = intensive glycaemic control; S = standard glycaemic control; CI = confidence interval; HR = hazard ratio; 
MI = myocardial infarction. *Medication rates for ACCORD are for any use during the study. 
hypoglycaemia during hospitalisation for AMI was a marker for more
severe illness and not necessarily a direct cause of it, providing some
reassurance to physicians in their efforts for glycaemic control in
patients. However, the question remains whether hypoglycaemia
resulting from certain drugs is harmful to patients.
Analyses of ACCORD do not show any definitive relationship between
the increased CV mortality in the intensive treatment arm and any
combination of drugs used. However, the combination of an SU and
metformin in ACCORD has previously been shown to be associated
with a significantly higher rate of CV events and trends towards a
higher rate of total mortality compared with SU or metformin
monotherapy treatment in the United Kingdom Prospective Diabetes
Study (UKPDS).35–37 Furthermore, a recent meta-analysis suggests that
the combination of an SU plus metformin in patients with type 2
diabetes, while having no significant effects on either CV disease
mortality or all-cause mortality alone, may increase the relative risk of
the composite end-point of CV hospitalisation or mortality (fatal and
non-fatal events). The authors presented several possible
explanations for their observation, one of which is the tendency of
SUs to cause hypoglycaemia, which may be further aggravated by the
metformin causing decreased hepatic glucose production, possibly
impairing the recovery from hypoglycaemia. However, the authors
highlight the limitations that exist in their meta-analysis and stress the
need for larger-scale studies to further characterise the results.38
Glyburide (glibenclamide), the most widely used SU, was linked to a
52% greater risk of experiencing at least one hypoglycaemic episode
compared with other secretagogues and an 83% greater risk
compared with other SUs;39 however, it was not associated with a
higher risk of CV events. 
These studies suggest a possible association between hypoglycaemia
and CV risk, leading to a need to find treatment options that have a
lower risk of hypoglycaemic events to prevent potential long-term CV
morbidity and mortality.
Hypoglycaemia and Other Co-morbidities
In addition to CV risk, hypoglycaemia may have an effect on risk of
dementia in older patients with type 2 diabetes.40 A longitudinal cohort
study was performed from 1980 to 2007 with 16,667 patients with a
mean age of 65 years with type 2 diabetes. Severe hypoglycaemic
episodes requiring hospitalisation significantly increased a patient’s
probability of developing dementia, with the risk increasing with more
episodes.40 Further research is required to determine the association
between minor episodes and risk of dementia. These results 
support the need for caution specifically in treating older patients 
with diabetes in order to limit the risk of dementia. They also illustrate
the complexities connected with diabetes treatment, as any
hypoglycaemia – caused by drugs or otherwise – may lead to a number
of unknown consequences for the patient.
Hypoglycaemia and Quality of Life
Hypoglycaemia and its symptoms may cause fear in patients with
diabetes and clinicians alike and can potentially lead to stress and an
impaired quality of life for patients and clinical inertia within the
medical community. Hypoglycaemic episodes have both short- and
long-term consequences on health-related quality of life (HRQoL). The
short-term consequences refer to the symptoms associated with 
the actual event. While hypoglycaemic episodes may be relatively
harmless, episodes can result in unconsciousness or impaired
cognition and thus situations may arise that can be detrimental for
both the patient and surrounding individuals.41 The long-term
consequences relate to changes in patient behaviour and their fear of
future episodes, resulting in negative social and emotional states.41,42
Fear of hypoglycaemia is one of the most problematic long-term
consequences.42 Patients who suffer hypoglycaemic episodes, even
non-severe episodes, are more likely to experience anxiety and panic
attacks that in turn can increase the number of episodes.41 An
important clinical implication resulting from a fear of hypoglycaemia is
reluctance by the patient and physician to intensify antidiabetes
therapy that may lead to a negative impact on diabetes management,
metabolic control and subsequent health outcomes.41,43 This clinical
inertia, which has been summarised as “the failure to initiate or
intensify therapy in a defined time among patients who have not
attained clinical goals and whom intensification is likely to benefit”,44 is
a limiting factor in diabetes treatment. Moreover, in an attempt to
avoid hypoglycaemia, some patients may alter treatment intensity and
overeat to elevate blood glucose levels.41 However, it has been shown
that blood glucose awareness training can reduce fear in patients.42
Individuals at High Risk and Clinical
Implications of Hypoglycaemia
Although many patients with diabetes are at risk of experiencing
hypoglycaemic episodes, there are factors that predispose certain
individuals to a greater risk. In older patients in particular, factors such
as a restricted carbohydrate intake, renal and hepatic dysfunction and
the effects of alcohol and medications in common use may increase
the risk of hypoglycaemia (see Table 3).45,46 These aspects, in
combination with SU or exogenous insulin therapy, make it more likely
that a patient will experience hypoglycaemia.46 An inadequate
glucagon response arising with long-standing diabetes, in particular in
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Table 3: Contributors to Increased Risk of
Severe Hypoglycaemia
Loss of Endogenous Insulin Secretion
Inability to reduce circulating insulin concentrations
Loss of signal to alpha-cells to increase glucagon secretion
Possible loss of C-peptide or amylin effects
Primary Failure of Hormones that Raise Blood Glucose Concentrations
Hypopituitarism
Adrenal cortical failure
Isolated growth hormone deficiency
Defective Glucose Counter-regulation
Loss of glucagon response to hypoglycaemia
Delayed onset of counter-regulatory response secondary to 
antecedent hypoglycaemia
Prolongation of Insulin Effect
Exogenous insulin injection
Insulin secretagogues
Renal impairment
Hyperthyroidism
High levels of insulin-binding antibodies
Liver failure
Exaggerated Mismatch Between Insulin and Nutrient Absorption
Primary gastrointestinal disease with malabsorption (coeliac disease)
Delayed insulin administration
Lifestyle Contributors to Individual Episodes of Severe Hypoglycaemia
Acute increase in muscle glucose uptake during exercise
Depletion of liver and muscle glycogen by vigorous/prolonged exercise
Suppression of gluconeogenesis by alcohol
Use of drugs enhancing effects of insulin secretagogues
type 1 diabetes, puts patients with diabetes at greater risk as defences
against hypoglycaemia are largely reduced.1 However, patients with
long-standing type 2 diabetes with endogenous insulin deficiency who
have been on insulin therapy for many years are also at increased risk
of severe hypoglycaemia.47 Patients with a history of repetitive
hypoglycaemia, in particular in combination with hypoglycaemia
unawareness, are at particular risk of severe hypoglycaemic attacks.
Furthermore, too aggressive glycaemic therapy resulting in lower
glycaemic goals, lower HbA1c levels or both can have also an effect on
future hypoglycaemic episodes.1
Finally, special attention should be given to those patients in whom
even mild hypoglycaemic attacks may have major consequences,
e.g. people in certain occupations (those working at heights or with
heavy machinery and occupational drivers) and people living alone.
In these circumstances, great care should be taken to avoid
hypoglycaemia altogether.
Given the potential severity of hypoglycaemic events and their
effect on the health of patients, it is important to minimise their
incidence. This can be accomplished by treating diabetes with drugs
that have a lower risk of hypoglycaemia, such as metformin,
thiazolidinediones and dipeptidyl peptidase-4 (DPP-4) inhibitors. The
inhibition of the DPP-4 enzyme by this latter new class of drugs
enhances the action of glucagon-like peptide-1 (GLP-1). As GLP-1
causes insulin secretion to increase only when glucose levels are
elevated, hypoglycaemia is less likely to occur.48 In fact, the UK’s
National Institute for Health and Clinical Excellence (NICE) has
recently recommended that DPP-4 inhibitors be used as a second-
line therapy for patients with type 2 diabetes if the person is at
significant risk of hypoglycaemia or its consequences. A recent
meta-analysis of randomised clinical trials studied the role of DPP-4
inhibitors in the treatment of type 2 diabetes and found that DPP-4
inhibitors lowered HbA1c with little or no weight gain or
hypoglycaemia risk. However, further study is needed to determine
the long-term safety profiles of this class of drug.49 Glitazones are
another class of type 2 diabetes therapy that have been studied as
a potential treatment with a low hypoglycaemia risk. These agents
work by helping the body use its available amounts of insulin more
effectively, thereby improving the patient’s insulin sensitivity. As a
result, glitazones are associated with a low incidence of
hypoglycaemia.50 However, when either drug class is used in
combination with SUs or insulin, the combination can still lead to
blood glucose levels dropping below normal.
Summary and Conclusions
Hypoglycaemia and its potentially serious consequences are a major
concern when managing patients with diabetes.22 Recurrent episodes
of hypoglycaemia, especially severe events, can lead to poor
treatment adherence in patients and a reluctance to intensify
treatment by health professionals, as well as having a negative
impact on patient quality of life. Hypoglycaemia was a predictor of CV
events in both ACCORD and VADT (although a causal relationship 
was not definitely established) and might precipitate other
morbidities, such as dementia. It would seem prudent to use
therapies that are associated with a lower risk of hypoglycaemia
(particularly in high-risk subjects) in an attempt to achieve optimal
and early glycaemic control in patients with type 2 diabetes, while
minimising the risk of adverse consequences. n
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